Baylor College of Medicine: CAR T Cell Therapy for T Cell Lymphoma Shows Promise in Phase I Trial
January 05, 2024
January 05, 2024
HOUSTON, Texas, Jan. 5 (TNSres) -- The Baylor College of Medicine issued the following news:
Researchers at the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital have developed a chimeric antigen receptor (CAR) T cell therapy targeting T-cell lymphoma, an aggressive and difficult to treat cancer. A first-in-human phase I clinical trial of patients with relapsed or refractory T cell lymphoma found early signals of . . .
Researchers at the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital have developed a chimeric antigen receptor (CAR) T cell therapy targeting T-cell lymphoma, an aggressive and difficult to treat cancer. A first-in-human phase I clinical trial of patients with relapsed or refractory T cell lymphoma found early signals of . . .